Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00931281 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00931281 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 38 participants.
The verdict
NCT00931281, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of multiple doses of an experimental hepatitis C virus (HCV) protease inhibitor with ritonavir in healthy volunteers.
Interventions
- DRUG ritonavir
- DRUG ABT-450
- DRUG Placebo for ritonavir
- DRUG Placebo for ABT-450
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00931281
The ClinicalTrials.gov registry entry for NCT00931281 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ritonavir is the first listed.
NCT00931281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00931281 about?
NCT00931281 is a clinical study titled "Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir". The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of multiple doses of an experimental hepatitis C virus (HCV) protease inhibitor with ritonavir in healthy volunteers.
What is the current status of trial NCT00931281?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2009-06.
What interventions are being tested in trial NCT00931281?
The interventions under investigation include: ritonavir (DRUG), ABT-450 (DRUG), Placebo for ritonavir (DRUG), Placebo for ABT-450 (DRUG).
Who is sponsoring clinical trial NCT00931281?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.